









Markets
/
Stocks
/
nasdaq-lung
/

Pulmonx Corp

LUNG

1.690USD

+0.090+5.62%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

68.86MMarket Cap

LossP/E TTM



Pulmonx Corp

1.690

+0.090+5.62%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

82 / 207

Overall Ranking

184 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

6.750

Target Price

+321.88%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 56.14% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 83.79M.

Overvalued

The company’s latest PE is -1.18, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 39.76M shares, decreasing 6.87% quarter-over-quarter.

Held by PRIMECAP Management

Star Investor PRIMECAP Management holds 5.16M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.32.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.92, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 23.86M, representing a year-over-year increase of 14.80%, while its net profit experienced a year-over-year increase of 1.00%.

Score

Industry at a Glance

Previous score

6.92

Change



Financials

8.17

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.90

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.10

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -1.12, which is 296.57% below the recent high of -4.44 and -484.24% above the recent low of -6.54.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 82/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.67, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Pulmonx Corp is 5.50, with a high of 16.00 and a low of 2.50.

Score

Industry at a Glance

Previous score

7.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

6.750

Target Price

+321.88%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Pulmonx Corp

LUNG

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.71, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 1.83 and the support level at 1.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.71

Change

0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.048

Neutral

RSI(14)

46.591

Neutral

STOCH(KDJ)(9,3,3)

42.575

Buy

ATR(14)

0.125

Low Volatility

CCI(14)

-3.193

Neutral

Williams %R

51.613

Neutral

TRIX(12,20)

-0.593

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.602

Buy

MA10

1.640

Buy

MA20

1.686

Buy

MA50

2.056

Sell

MA100

2.614

Sell

MA200

4.624

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 97.74%, representing a quarter-over-quarter increase of 0.05%. The largest institutional shareholder is PRIMECAP Management, holding a total of 5.16M shares, representing 12.68% of shares outstanding, with 9.20% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

PRIMECAP Management Company

Star Investors

5.41M

-1.77%

Fidelity Management & Research Company LLC

4.71M

-8.61%

Morgan Stanley & Co. LLC

2.93M

+15.68%

BlackRock Institutional Trust Company, N.A.

2.54M

-1.48%

The Vanguard Group, Inc.

Star Investors

2.28M

-0.05%

Deerfield Management Company, L.P.

1.89M

+23.15%

BNP Paribas Asset Management USA, Inc.

1.25M

DWS Investments UK Limited

1.13M

+2.82%

Silvercrest Asset Management Group LLC

930.56K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.42. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.